"So as such, RVX208 does not raise or lower eGFR; is that right?"

In my previous post, I was referring to cardiovascular outcomes data. As for changes in eGFR, the previous Phase 2 data suggests that apabetalone/RVX-208 increases eGFR in CKD patients with eGFR<60. We are awaiting the Phase 3 BETonMACE CKD sub-study results to be revealed to find out if apabetalone/RVX-208 raised eGFR in those patients with baseline eGFR<60. All we know right now is that in the TOTAL population in BETonMACE (>2400 patients, median baseline eGFR 99) that there was a small eGFR decrease of 0.4 in the apabetalone group and a small eGFR increase of 2.1 in the placebo group. As far as I know, Resverlogix never shared any eGFR data from Phase 2s in patients with normal kidney function. Although this trend seems to go in the wrong direction, it is clinically insignificant in my opinion, since the total population is dominated by folks with normal kidney function (median 99). We need to see those ~240 or so CKD patients by themselves and see if apabetalone/RVX-208 improves kidney function there. I am still expecting to see kidney function deteriorate in the placebo group and improve in the apabetalone/RVX-208 group.

BDAZ